// App-Quantinova.ai

2017 : The CEBPD transcription factor, a marker of good prognosis in breast cancer, becomes a signaling hub for promotion of cancer cell stemness by hypoxia and interleukin-6

Researchers

Presenter

  • Kuppusamy Balamurugan

Principal Investigators

  • Daniel Mendoza-Villanueva

  • Barbara Rath

  • Philip Tofilon

  • Shikha Sharan

  • Esta Sterneck

Medical Centers

  • CCR, NCI, NIH, Frederick, MD.

  • NCI-CCR, Bethesda, MD.

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Glioblastoma

  • Solid malignancies

Biomarkers

  • CCAAT enhancer binding protein delta

  • Cluster of Differentiation 44

  • Prominin 1

  • Hypoxia-inducible factor-1

  • Interleukin 6

  • Kruppel-like factor 4

  • Signal transducer and activator of transcription 3

Drug/Treatment

  • ILS-969

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved